Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and related disorders. Myelin seems to be the primary target ...
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s ...
Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status ...
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, ...
Big Pharma-backed immunomodulation biotech Nuvig Therapeutics is moving its lead asset into phase 2 trials using a $161 ...
California-based biotech Nuvig Therapeutics scooped up $161 million from the investment arms of Sanofi, Bayer, Novo Holdings, ...
000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...
000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback